Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2019-10-29 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Science Update - Anti-Fibrotic Pipeline 3 pages 127.8KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 30 October 2019 from Pharmaxis Ltd providing an update on its anti-fibrotic drug pipeline, including details about its LOXL2 and pan-LOX inhibitors, pre-clinical data, and plans for clinical trials. It discusses scientific data, competitive positioning, and partnering efforts but does not contain financial statements or detailed financial performance data. The document is a corporate update or press release rather than a formal financial report or regulatory filing. It is not an earnings release, annual or interim report, or any other formal filing type. Given the content and nature, it fits best as a Regulatory Filing (RNS) which is the fallback category for miscellaneous corporate announcements and updates that do not fit other specific categories.
2019-10-29 English
FDA Provides Guidance on Bronchitol Approval Steps 2 pages 107.0KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 28 October 2019 from Pharmaxis Ltd announcing FDA guidance on the approval steps for Bronchitol, including expected timing for FDA review completion in Q2 2020. It discusses regulatory updates, study protocols, and commercial arrangements but does not contain financial statements, detailed financial results, or comprehensive report data. The document is a public announcement about regulatory progress and timelines rather than a formal financial report or detailed investor presentation. It is not an earnings release, annual or interim report, or audit report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and update on FDA approval progress without substantive financial data or detailed report content.
2019-10-27 English
Pharmaxis Cancer Drug Progressing in Clinic 2 pages 160.6KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 24 October 2019 from Pharmaxis Ltd announcing progress in a clinical drug trial (Phase 1B following positive Phase 1A data) for an oral pan-LOX inhibitor targeting cancer treatment. It discusses clinical trial stages, study results, and future plans including discussions with the FDA. The content is focused on clinical development updates and company progress rather than financial results, regulatory filings, or shareholder information. It is not an earnings release, annual report, or any financial report. It is also not a regulatory filing or announcement of a report publication. The document is a corporate announcement about drug development progress, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories like earnings, capital updates, or management changes. The document length (6600 characters) and content confirm it is a detailed announcement but not a financial or governance report.
2019-10-23 English
Annual Report to shareholders 64 pages 799.6KB
Annual Report Classification · 95% confidence The document is titled 'Statutory Annual Report 2019' and mentions lodging with the Australian Securities Exchange and the Australian Securities and Investments Commission, indicating it is an official annual report. The length is substantial (15,000 characters), suggesting it contains detailed financial and operational information rather than just an announcement. The text references consolidated financial statements and forward-looking statements typical of an annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2019-10-17 English
Notice of Annual General Meeting/Proxy Form 14 pages 330.6KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF THE 2019 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and includes details about the date, time, and location of the AGM, proxy voting instructions, and the agenda items to be discussed at the meeting. It contains no actual financial statements or detailed financial data but rather serves as a notice and explanatory statement for the upcoming AGM. The document references the company's 2019 statutory annual report as being available elsewhere, indicating this document is not the annual report itself. The content aligns with materials typically distributed to shareholders prior to an AGM to inform them of the meeting and resolutions to be voted on. Therefore, this document fits the category of AGM Information (AGM-R).
2019-10-17 English
Corporate Governance Statement 18 pages 85.5KB
Governance Information Classification · 100% confidence The document is titled 'Copy of Corporate Governance Statement – 2019' and contains detailed information about the company's corporate governance framework, board structure, policies, and practices. It references the ASX Corporate Governance Principles and Recommendations and discusses board roles, director independence, diversity policies, and performance evaluations. There is no financial data, earnings information, or audit results presented. The content aligns with a report detailing the company's internal rules, board structure, and governance practices, which fits the definition of a Governance Information (CGR) filing. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or summary.
2019-10-17 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.